ERBB2 and breast cancer: DESTINY-Breast03 demonstrated the superiority of T-Dxd when treating HER2-positive breast cancer with BMETS when compared to trastuzumab emtasine (percent of patients alive at 12 months without disease progression: 75.8% vs. 34.1%, respectively) [7].